Protect and strengthen democratic society today and for the future. Invest in AllSides
Protect and strengthen democratic society today and for the future. Invest in AllSides
Protect and strengthen democratic society today and for the future. Invest in AllSides

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

Invest in

Invest in

Invest in

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

 

 

 

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

https://www.nbcnews.com/science/science-news/strong-covid-immunity-blood-test-o…
Type of Content
Approved Story
1
Format
Region
News Item Format
Standard
Image Caption
Getty Images/Image Source

A newly developed blood test that measures a specific immune response in the body could help doctors gauge how much protection a person has against Covid-19, according to a new study.

The test, which focuses on the part of the immune system that confers long-term protection by prompting the body to "remember" the virus, could help make sense of the complex tangle of Covid immunity that now exists from person to person.

The test can, for instance, measure immunity regardless of whether someone has developed a level of protection from one or more natural infections or from vaccinations and booster shots. Others, who may have much lower levels of protection because they are immunocompromised, could also use the test to assess their vulnerability and see how they responded to the vaccines, said Ernesto Guccione, an associate professor of oncological sciences and pharmacological sciences at the Tisch Cancer Institute at Mount Sinai.

"Ideally, it will give you a full picture of where you stand and a comprehensive picture of your immune protection," said Guccione, one of the authors of the study published Monday in the journal Nature Biotechnology. 

The researchers said they are focused next on clinical trials in order to gain approval from both the Food and Drug Administration and the European Medicines Agency.